CureVac N.V (NASDAQ: CVAC) has a higher price-to-earnings ratio of 6.04x compared to its average ratio, The 36-month beta value for CVAC is at 2.51. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for CVAC is 93.61M, and currently, shorts hold a 3.88% of that float. The average trading volume for CVAC on February 21, 2025 was 791.18K shares.
CVAC) stock’s latest price update
CureVac N.V (NASDAQ: CVAC)’s stock price has plunge by 0.00relation to previous closing price of 3.28. Nevertheless, the company has seen a -10.14% plunge in its stock price over the last five trading sessions. accessnewswire.com reported 2025-02-18 that CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio The company holds one of the broadest intellectual property portfolios in mRNA technology TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / February 18, 2025 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced its recognition as a Top 100 Global Innovator in the Innovation Momentum 2025 report by LexisNexis®.
CVAC’s Market Performance
CureVac N.V (CVAC) has seen a -10.14% fall in stock performance for the week, with a -17.17% decline in the past month and a 27.13% surge in the past quarter. The volatility ratio for the week is 5.07%, and the volatility levels for the past 30 days are at 5.42% for CVAC. The simple moving average for the past 20 days is -10.05% for CVAC’s stock, with a -1.05% simple moving average for the past 200 days.
Analysts’ Opinion of CVAC
Many brokerage firms have already submitted their reports for CVAC stocks, with Leerink Partners repeating the rating for CVAC by listing it as a “Market Perform.” The predicted price for CVAC in the upcoming period, according to Leerink Partners is $4 based on the research report published on April 25, 2024 of the previous year 2024.
SVB Securities, on the other hand, stated in their research note that they expect to see CVAC reach a price target of $13. The rating they have provided for CVAC stocks is “Outperform” according to the report published on June 08th, 2023.
UBS gave a rating of “Buy” to CVAC, setting the target price at $18 in the report published on January 19th of the previous year.
CVAC Trading at -8.59% from the 50-Day Moving Average
After a stumble in the market that brought CVAC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.88% of loss for the given period.
Volatility was left at 5.42%, however, over the last 30 days, the volatility rate increased by 5.07%, as shares sank -17.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.81% upper at present.
During the last 5 trading sessions, CVAC fell by -10.14%, which changed the moving average for the period of 200-days by +4.79% in comparison to the 20-day moving average, which settled at $3.65. In addition, CureVac N.V saw -3.81% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CVAC starting from Myriam Mendila, who proposed sale 17,839 shares at the price of $4.93 back on Jan 07 ’25. After this action, Myriam Mendila now owns shares of CureVac N.V, valued at $88,019 using the latest closing price.
Pierre Kemula, the affiliate of CureVac N.V, proposed sale 51,523 shares at $4.93 during a trade that took place back on Jan 07 ’25, which means that Pierre Kemula is holding shares at $254,219 based on the most recent closing price.
Stock Fundamentals for CVAC
Current profitability levels for the company are sitting at:
- 0.24 for the present operating margin
- 0.7 for the gross margin
The net margin for CureVac N.V stands at 0.2. The total capital return value is set at 0.17. Equity return is now at value 17.08, with 13.38 for asset returns.
Based on CureVac N.V (CVAC), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at 3.2. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is 206.04.
Currently, EBITDA for the company is -234.09 million with net debt to EBITDA at -3.28. When we switch over and look at the enterprise to sales, we see a ratio of 0.35. The receivables turnover for the company is 26.09for trailing twelve months and the total asset turnover is 0.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.20.
Conclusion
In conclusion, CureVac N.V (CVAC) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
